drugset / Trial / NCT06567080
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
Phase 1
Not yet recruiting
15 enrolled
RenJi Hospital
Shanghai Mingju Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
JWCAR201 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR201 in patients with B cell driven hematology malignancy and autoimmune diseases
Timeline
- Start
- 2024-09
- Primary completion
- 2025-09
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JWCAR201 | Cell therapy | — | — |